Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2877

1.

CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.

Ning Y, Wang C, Liu X, Du Y, Liu S, Liu K, Zhou J, Zhou C.

J Exp Clin Cancer Res. 2019 Mar 18;38(1):131. doi: 10.1186/s13046-019-1137-8.

PMID:
30885251
2.

A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.

Luo T, Zhang SG, Zhu LF, Zhang FX, Li W, Zhao K, Wen XX, Yu M, Zhan YQ, Chen H, Ge CH, Gao HY, Wang L, Yang XM, Li CY.

J Exp Clin Cancer Res. 2019 Mar 18;38(1):130. doi: 10.1186/s13046-019-1104-4.

PMID:
30885237
3.

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.

Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, Ai B, Cao X, Guo T, Liao Y.

J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. doi: 10.1186/s13046-019-1120-4.

4.

GAGE7B promotes tumor metastasis and growth via activating the p38δ/pMAPKAPK2/pHSP27 pathway in gastric cancer.

Shi DB, Ma RR, Zhang H, Hou F, Guo XY, Gao P.

J Exp Clin Cancer Res. 2019 Mar 11;38(1):124. doi: 10.1186/s13046-019-1125-z.

5.

Cell communication and signaling: how to turn bad language into positive one.

Chiodoni C, Di Martino MT, Zazzeroni F, Caraglia M, Donadelli M, Meschini S, Leonetti C, Scotlandi K.

J Exp Clin Cancer Res. 2019 Mar 13;38(1):128. doi: 10.1186/s13046-019-1122-2.

6.

Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases.

Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):125. doi: 10.1186/s13046-019-1123-1.

7.

Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer.

Xiong Y, He L, Shay C, Lang L, Loveless J, Yu J, Chemmalakuzhy R, Jiang H, Liu M, Teng Y.

J Exp Clin Cancer Res. 2019 Mar 11;38(1):122. doi: 10.1186/s13046-019-1124-0.

8.

MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12.

He Z, Guo X, Tian S, Zhu C, Chen S, Yu C, Jiang J, Sun C.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):126. doi: 10.1186/s13046-019-1105-3.

9.

A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors.

Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):127. doi: 10.1186/s13046-019-1121-3.

10.

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.

Fang L, Ly D, Wang SS, Lee JB, Kang H, Xu H, Yao J, Tsao MS, Liu W, Zhang L.

J Exp Clin Cancer Res. 2019 Mar 11;38(1):123. doi: 10.1186/s13046-019-1126-y.

11.

The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.

Xu N, Hua Z, Ba G, Zhang S, Liu Z, Thiele CJ, Li Z.

J Exp Clin Cancer Res. 2019 Mar 8;38(1):118. doi: 10.1186/s13046-019-1107-1.

12.

MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression.

Soni S, Anand P, Padwad YS.

J Exp Clin Cancer Res. 2019 Mar 8;38(1):121. doi: 10.1186/s13046-019-1115-1. Review.

13.

Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.

Zhang L, Zhou R, Zhang W, Yao X, Li W, Xu L, Sun X, Zhao L.

J Exp Clin Cancer Res. 2019 Mar 8;38(1):120. doi: 10.1186/s13046-019-1117-z.

14.

TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.

Yin X, Wang B, Gan W, Zhuang W, Xiang Z, Han X, Li D.

J Exp Clin Cancer Res. 2019 Mar 8;38(1):119. doi: 10.1186/s13046-019-1101-7.

15.

Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress.

Zhang Q, Yu S, Lam MMT, Poon TCW, Sun L, Jiao Y, Wong AST, Lee LTO.

J Exp Clin Cancer Res. 2019 Mar 7;38(1):116. doi: 10.1186/s13046-019-1127-x.

16.

Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.

Xu W, Qian J, Zeng F, Li S, Guo W, Chen L, Li G, Zhang Z, Wang QJ, Deng F.

J Exp Clin Cancer Res. 2019 Mar 6;38(1):114. doi: 10.1186/s13046-019-1118-y.

17.

Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology.

Nissen NI, Karsdal M, Willumsen N.

J Exp Clin Cancer Res. 2019 Mar 6;38(1):115. doi: 10.1186/s13046-019-1110-6. Review.

18.

Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma.

Peng R, Zhang PF, Yang X, Wei CY, Huang XY, Cai JB, Lu JC, Gao C, Sun HX, Gao Q, Bai DS, Shi GM, Ke AW, Fan J.

J Exp Clin Cancer Res. 2019 Mar 5;38(1):113. doi: 10.1186/s13046-019-1113-3.

19.

FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.

Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W.

J Exp Clin Cancer Res. 2019 Mar 4;38(1):112. doi: 10.1186/s13046-019-1043-0.

20.

Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells.

Gao R, Zhang N, Yang J, Zhu Y, Zhang Z, Wang J, Xu X, Li Z, Liu X, Li Z, Li J, Kong C, Bi J.

J Exp Clin Cancer Res. 2019 Mar 1;38(1):111. doi: 10.1186/s13046-019-1102-6.

Supplemental Content

Loading ...
Support Center